Part1.What is active hexose correlated compound supplement(AHCC) ?
Active Hexose Correlated Compound (AHCC) is a group of chemicals that are taken from fungi, like mushrooms, and turned into a supplement. People take this supplement to help their immune system.
Part2.What are the potential uses and benefits?
AHCC is taken to:
1.Treat cancer
2.Treat infections
3.Improve liver function
While AHCC is used for these reasons, there isn’t enough research to say that it works. Talk with your healthcare provider before taking AHCC.
Part3.A new study on AHCC
Recently, an article about AHCC Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections was published in the journal Frontiers in Oncology. The researchers have gotten a conclusion:Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported.
Part4.Clinical application
1.Active hexose correlated compound (AHCC) is a proprietary extract derived from the mycelia of shiitake (Lentinus edodes) mushrooms. It is rich in alpha-1,4-glucan oligosaccharides that are thought to enhance its biological effects . Patients use AHCC to prevent and treat cancer.
2.AHCC showed anti-inflammatory and anticancer effects, enhanced resistance to microbial infections , and may protect against oxidative stress-induced disorders . In healthy adults, AHCC improved T-cell immune responses , increased dendritic cell number and function , improved antibody response to influenza vaccine, and when used with Bifidobacterium longum, modulated T regulatory and dendritic cell phenotypes to favor anti-inflammatory responses after antibiotic use.
3.Preliminary findings suggest that AHCC may improve prognosis and prevent recurrence after curative resection of hepatocellular carcinoma , improve nutritional status when given during neoadjuvant therapy, and reduce chemo-associated adverse effects. However, in an open-label multicenter study of patients with early stage prostate cancer, AHCC was ineffective in reducing prostate-specific antigen levels by 50% or more . Further research is needed to determine the therapeutic potential of this extract.
